Tata AIG insurance has become the third insurer to suspend cashless claim services with Max Hospitals
What started as a localised issued between Bajaj Allianz and AHPI, has turned out to become a health insurance sector issue with more players latching on to problem
Motilal Oswal is bullish on Niva Bupa has recommended buy rating on the stock with a target price of Rs 101 in its research report dated August 07, 2025.
Motilal Oswal is bullish on Niva Bupa has recommended buy rating on the stock with a target price of Rs 101 in its research report dated July 31, 2025.
Motor insurance saw a pull back, fire made a comeback and health continued to grow in the June quarter as ICICI Lombard, SBI General, Shriram General and Niva Bupa adapted to pricing and policy shifts
Krishnan Ramachandran, CEO, says the health insurer’s internal goal is to grow 5-10 percentage points faster than the overall health insurance industry
Promoter Bupa increasing its stake in Niva Bupa would depend on liquidity conditions, he said. "We’ll continue to look for opportunities in group accounts, but retail will remain our primary focus," Mahendra said.
The insurer recorded an 18.2 percent year-on-year growth in gross premiums written for the fourth quarter of FY25, reaching Rs 2,078.7 crore compared to Rs 1,759.4 crore in the same period last year.
Morgan Stanley touted Niva Bupa as a "strong franchise with a secular growth opportunity." The brokerage views the health insurer as well positioned to take advantage of the growth in India's health insurance sector.
While the company is growing at a fast pace, the proposed composite licence in the insurance sector is one big impediment Niva Bupa may face
The proposed hike in GST for demerit goods has impacted several stocks tied to these industries. Meanwhile, insurance stocks saw positive movement amid expectations of tax cuts on insurance premiums.
The GoM on rate rationalisation under Bihar Deputy CM proposed to reduce GST from 18% to 5% on health insurance premia
The insurance firm showed efficiency improvements, with the combined ratio falling to 101.3 percent from the previous quarter. Its claim settlement ratio also improved to 91.4 percent.
Niva Bupa shares make a decent stock market debut on exchanges after a heathy subscription of 1.80 times to its Rs 2,200-crore issue.
Analysts predict a subdued opening for the shares of the company amid a volatile market and a tepid demand for shares in the grey market.
Niva Bupa IPO GMP is indicating a flat listing for company's shares on the exchanges on Thursday, November 13.
Business news highlights (November 11): The Bangalore-based firm, backed by investors like Peak XV Partners and Lightspeed India Partners, has engaged in discussions with investment banks to prepare for a potential IPO in Mumbai next year.
Low penetration of health insurance, high out-of-pocket expenses, consistently higher healthcare inflation, and increased awareness are some of the structural factors that will drive the demand for retail healthcare insurance
Analysts underscored the company's expertise in claims and provider management alongside a diverse product portfolio tailored to meet various customer needs, as key strengths of the company.
Niva Bupa's Rs 2,200-crore IPO is set to open on Thursday and will be partly a new share sale and part offer for sale.
Four years after picking up a majority stake from Max in Max Bupa Health Insurance (later Niva Bupa Health Insurance), True North ceded control to JV partner Bupa in September 2023
The Rs 2,200-crore IPO is a combination of fresh issue of Rs 800 crore and an offer-for-sale of Rs 1,400 crore worth of shares by promoters
This collaboration builds upon Niva Bupa's existing relationship with Fincare Small Finance Bank, which has now merged with AU SFB.
Niva Bupa's plans are the latest example of India's booming IPO markets, where investors are pouring record amounts of money into small and big companies.
Niva Bupa is likely to raise nearly Rs 600-800 crore through fresh issuance of shares and the OFS size is likely to be between Rs 2,200-2,400 crore